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Abstract
Aims/hypothesis Homozygosity for glycine at codon 16
(GlyGly) of the β2-adrenergic receptor may alter receptor
sensitivity upon chronic stimulation and has been implicated
in the pathogenesis of hypoglycaemia unawareness. We
compared the effect of antecedent hypoglycaemia on β2-
adrenergic receptor sensitivity between GlyGly participants
and those with arginine 16 homozygosity (ArgArg) for the
β2-adrenergic receptor.
Methods We enrolled 16 healthy participants, who were
either GlyGly (n=8) or ArgArg (n=8). They participated
randomly in two 2 day experiments. Day 1 consisted of two
2-h hyperinsulinaemic hypoglycaemic (2.8 mmol/l) or eugly-
caemic (4.8 mmol/l) glucose clamps. On day 2, we measured
theforearmvasodilatorresponsetotheβ2-adrenergic receptor
agonist salbutamol and the dose of isoprenaline required to
increase the heart rate by 25 bpm (IC
25).
Results The vasodilator response to salbutamol tended to be
greater after antecedent hypoglycaemia than after euglycae-
mia (p=0.078), consistent with increased β2-adrenergic
receptor sensitivity. This effect was driven by a significant
increase in β2-adrenergic receptor sensitivity following
hypoglycaemia compared with euglycaemia in ArgArg
participants (p=0.019), whereas no such effect was observed
in the GlyGly participants. Antecedent hypoglycaemia
tended to decrease the IC
25 in ArgArg participants, whereas
the reverse occurred in the GlyGly participants (GlyGly vs
ArgArg group p=0.047).
Conclusion/interpretation Antecedent hypoglycaemia did
not affect β2-adrenergic receptor sensitivity in healthy
GlyGly participants, but increased it in ArgArg participants.
If these results also hold for participants with type 1
diabetes, such an increase in β2-adrenergic receptor
sensitivity may potentially reduce the risk of repeated
hypoglycaemia and the subsequent development of hypo-
glycaemia unawareness in ArgArg diabetic participants.
Trial registration ClinicalTrials.gov NCT00160056
Funding Radboud University Nijmegen Medical Centre.
Keywords Adrenergic beta-2.Hypoglycaemia.Genome.
Polymorphism single nucleotide.Receptors.Adrenergic.
Type 1 diabetes
Abbreviations
ArgArg Homozygous arginine
ArgGly Heterozygous arginine/glycine
FBF Forearm blood flow
GlyGly Homozygous glycine
IC
25 Isoprenaline concentration that increases the
heart rate by 25 beats/min
SNP Single nucleotide polymorphism
Introduction
Despite important advances in insulin treatment and
glucose control, hypoglycaemia remains a fact of life for
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episodes are known to impair glucose counter-regulatory
defences and to reduce hypoglycaemic awareness [1–3].
Indeed, impairments in counterregulatory hormone responses
to, and symptomatic perception of, insulin-induced hypo-
glycaemia can be induced by as few as two hypoglycaemic
episodes, even in healthy participants [4–6]. However,
although most patients with type 1 diabetes experience
hypoglycaemia on a fairly regular basis, clinically relevant
hypoglycaemia unawareness affects ‘only’ about 25% of
patients [7]. This suggests involvement of other factors that
determine the susceptibility to developing hypoglycaemia
unawareness.
Genetic factors have been implicated in the risk for
hypoglycaemia and hypoglycaemia unawareness in patients
with type 1 diabetes [8, 9]. We recently found that the
prevalence of hypoglycaemia unawareness was in part
determined by a SNP in the gene encoding the β2-
adrenergic receptor (ADRB2) [10]. Thus, patients who
were GlyGly at codon 16 of the β2-adrenergic receptor
were more likely to report hypoglycaemia unawareness
than those who were ArgGly or ArgArg.
The SNP occurring at position 46 of ADRB2, encoding
for arginine or glycine at the N-terminus (codon 16) of the
β2-adrenergic receptor, may determine the degree to which
β2-adrenergic receptors lose sensitivity when chronically
stimulated. Although in vitro studies have displayed
discrepant results [11], most in vivo data indicate that
substitution of glycine for arginine at codon 16 reduces
sensitivity of the β2-adrenergic receptor upon chronic
stimulation [12, 13]. This might be a potential mechanism
in the development of hypoglycaemia unawareness since
recurrent hypoglycaemic episodes and the consequent
release of catecholamine’s may alter β2-adrenergic receptor
sensitivity. Reduced β-adrenergic sensitivity has been
reported in relation to hypoglycaemia unawareness, based
on reduced heart rate responses to isoprenaline, a non-
selective β-adrenergic agonist [14–18]. In addition, there is
some suggestion that this reduced sensitivity was mediated
through the β2-adrenergic receptor [19, 20]. Mixed effects
were seen in healthy participants, with one study showing
reduced [21], and another showing increased, β-adrenergic
sensitivity [15] after a period of hypoglycaemia. The effect
of antecedent hypoglycaemia on β2-adrenergic sensitivity
alone has not been determined. Further, it could be argued
that genetic variation of the β2-adrenergic receptor explains
the abovementioned disparate effects of hypoglycaemia on
β-adrenergic sensitivity in patients and healthy participants.
The aims of this study were first to investigate whether
two episodes of antecedent hypoglycaemia, a stimulus
known to induce hypoglycaemia unawareness [4, 5], would
decrease next day β2-adrenergic sensitivity in healthy
participants, and second, to investigate this more particu-
larly in participants who were GlyGly compared with
ArgArg.
Methods
Participants Healthy participants (n=96) were selected by
advertisement and genotyped for the Arg/Gly polymor-
phism in ADRB2. Of these, 16 participants were enrolled in
the present study: eight GlyGly (one male, mean age 22±
1 years, mean BMI 21.2±1.3 kg/m
2) and eight ArgArg
(four male, mean age 22±1 years, mean BMI 21.2±0.4 kg/
m
2). None of the participants were allowed to use any
medication except oral contraceptives. They were asked to
abstain from alcohol and caffeine containing products for
24 h and from food intake at least 10 h before experiments
took place. All participants gave their written informed
consent. The study was approved by the Radboud University
Nijmegen Medical Centre Medical Ethics Committee and
carried out in accordance with the principles of the
Declaration of Helsinki as revised in 2000.
Experimental design We performed a randomised con-
trolled crossover study, comparing the effects of antecedent
hypoglycaemia with those of antecedent euglycaemia.
Participants participated in two experiments, each consist-
ing of two consecutive days and scheduled at least 3 weeks
apart. Female participants were studied during the same
period of the menstrual cycle. The aim of day 1 was to
induce hypoglycaemia unawareness by two consecutive
episodes of hypoglycaemia, whereas the control experiment
consisted of two comparable episodes of euglycaemia. The
aim of day 2 was to quantify β2-adrenergic and overall β-
adrenergic sensitivity by measuring the vasodilator re-
sponse to salbutamol and the heart rate response to
isoprenaline, respectively. All experiments took place at
the Clinical Research Centre Nijmegen (CRCN) in a
temperature controlled room (temperature 23–24°C).
First experiment day 1 All participants were admitted to
the CRCN at 08:00 hours after an overnight fast. Two
indwelling catheters were inserted intravenously. One
catheter was placed in retrograde fashion into a dorsal hand
vein for blood sampling. This hand was placed in a heated
box (55–60°C) to obtain arterialised venous blood [22]. The
second catheter was inserted in the antecubital vein of the
contralateral arm for infusion of insulin (Actrapid; Novo
Nordisk, Bagsvaerd, Denmark) and glucose. At t=0 min,
infusion of insulin was initiated at a rate of 60 mU m
−2 min
−1
after a bolus of 1 U. Plasma glucose was maintained at
predetermined levels using a variable infusion of glucose
20%, based on plasma glucose levels measured in duplicate
at 5 min intervals by the glucose oxidase method using a
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erton, CA).The plasmaglucose targetwas ~4.8mmol/l during
the euglycaemic clamps and ~2.8 mmol/l during the
h y p o g l y c a e m i cc l a m p s .T h e s el e v e l sw e r er e a c h e dw i t h i n
45 min and then maintained for 120 min. Subsequently, the
insulin infusion was discontinued, euglycaemia was main-
tained (euglycaemia) or restored (hypoglycaemia), and the
participants received a small snack. After 120 min, the clamp
procedure was repeated in the afternoon. At t=450 min, the
insulin infusion was terminated, glucose was continued as
required to restore and maintain euglycaemia and participants
received a carbohydrate-rich meal before they left the
research unit at approximately 18:00 hours. Arterialised
blood was sampled for measurement of catecholamines,
insulin, glucagon and cortisol at baseline, and at t=45, 105,
165, 330, 390 and 450 min. Before initiation of, and at 20-
min intervals during the clamp procedures, the appearance of
hypoglycaemic symptoms was checked using a semi-
quantitative symptom questionnaire [23] consisting of non-
specific (not feeling well, nausea, headache), adrenergic
(tremor, palpitations), cholinergic (hunger, sweating, dry
mouth, tingling), neuroglycopenic (difficulty speaking,
blurred vision, difficulty to concentrate, confusion, tiredness,
weakness) and dummy symptoms (pain in legs, yellow
vision). Participants were asked to score these items from 0
(absent) to 6 (very severe). In addition, they were also asked
to score to what extent they felt hypoglycaemic.
First experiment day 2 Participants were re-admitted to the
CRCN at 08:00 hours the next morning after an overnight
fast. The brachial artery of the non-dominant arm was
cannulated (Angiocath 20-gauche; Deseret Medical, Sandy,
UT, USA) under local anaesthesia (xylocaine 2%) for
infusion of salbutamol and continuous blood pressure
monitoring. An indwelling catheter was inserted into the
antecubal vein of the contralateral arm for infusion of
isoprenaline. Intra-arterial infusion rates of salbutamol were
calculated per 100 ml forearm volume, measured by water
displacement. After cannulations, a 30-min equilibration
period was allowed to pass before baseline variables were
obtained. Subsequently, 5-min infusions of saline and
incremental doses of salbutamol (Ventolin; GlaxoSmithK-
line, Zeist, the Netherlands) diluted in a saline vehicle
(0.003, 0.01, 0.03, 0.1, 0.3, 1.0 μg/min per 100 ml of
forearm tissue) were administered intra-arterially [24].
Forearm blood flow (FBF) was measured during the final
2 min of each dosing step in both arms, using ECG-
triggered mercury-in-silastic strain gauge venous occlusion
plethysmography as described previously [25]. Wrist cuffs
inflated to 220 mmHg eliminated the hand circulation
during FBF measurements [26]. The successive salbutamol
doses were interrupted once by a 15-min drug-free interval
for deflation of the wrist cuffs to allow recovery of hand
circulation. The mean of eight FBF measurements was used
for data analysis.
Thirty minutes after the FBF measurements, the isopren-
aline sensitivity test was carried out [15, 27]. Participants
were connected to a computer-assisted ECG (Fysioflex
System, Nijmegen, the Netherlands) for determination of
the heart rate response. Intra-arterial blood pressure was
also recorded. Isoprenaline (Pharmacy department, Univer-
sity Medical Centre Groningen, the Netherlands) diluted in
saline was injected intravenously as a 5 ml bolus infusion in
incremental doses of 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0
and 4.0 μg or until the heart rate increased by >25 bpm.
Each dose was given 2 min after the heart rate had returned to
baseline level (approximately 5 min after the previous
injection). The basal heart rate was defined as the mean heart
rate for the 20 s before the first injection. The maximal heart
rate was usually reached approximately 30–60 s following
each injection. The maximal heart rate was determined as the
mean of the three shortest consecutive RR intervals following
each injection. β-Adrenergic sensitivity was expressed as the
dose of isoprenaline that increased the heart rate by 25 bpm
over baseline values (IC
25)[ 15].
Analytical procedures After genomic DNA isolation from
blood [28], genotyping of the A/G (rs1042713) polymor-
phism in ADRB2 was performed by pyrosequencing [29]
according to the manufacturer’s protocol (Pyrosequencing,
Uppsala, Sweden). Further details are provided in the
electronic supplementary material.
The total symptom score was calculated separately for
each category at each time point. The means of the scores
obtained during the morning and afternoon clamp were used
for analysis. Blood samples for glucose measurements were
centrifuged immediately. Arterialised blood for determina-
tion of catecholamines, insulin, glucagon and cortisol was
kept on ice before centrifugation and then stored at −80°C
for later analysis. Plasma adrenaline (epinephrine) and
noradrenaline (norepinephrine) were analysed by HPLC
with fluorometric detection, as described previously [30].
Plasma insulin was assessed by RIA using a human insulin
standard (Novo Biolabs no 471), plasma glucagon was
measured by competitive RIA using a reagent kit from
Eurodiagnostica (Malmö, Sweden) and plasma cortisol was
measured by Luminescence Immunoassay on an Architect
randomaccessanalyser(Abbott,Hoofddorp,the Netherlands)
[31]. The final two measurements during the morning clamps
(i.e. t=105 and t=165 min) and the afternoon clamps (i.e. t=
390 and t=450 min) were averaged for analysis.
Second experiment day 1 and day 2 With an interval of at
least 3 weeks, all subjects returned for the second set of
experiments. Participants who underwent a euglycaemic
clamp on day 1 of the first experiment underwent a
1214 Diabetologia (2011) 54:1212–1218hypoglycaemic clamp on day 1 of the second experiment
and vice versa. Procedures of days 1 and 2 were similar to
those described above for the first experiment
Data analysis and statistical procedure To detect differ-
ences in β2-adrenergic sensitivity between the hypoglycae-
mia and euglycaemia study arms (as measured by
quantifying the forearm vasodilator response to salbutamol
infusion), we calculated that a sample size of eight
participants was required to reach a power of 80% to find
a 25% difference at a two-sided significance level of 5%.
Statistical analyses were performed using SPSS (software
package 16.0). Differences in the means of continuous
measurements were tested by two tailed Student’s t test.
Vasodilator responses to salbutamol were expressed as
absolute FBF. The effect of salbutamol on FBF was
analysed by repeated-measures ANOVA. The IC
25 was
determined by calculating sigmoidal dose–response curves
for each participant using Graphpad software (version
4.02). The IC
25 levels following euglycaemia and hypo-
glycaemia were compared with paired or independent
Student’s t tests as appropriate. p<0.05 was considered
statistically significant. Data are presented as means±SEM.
Results
Insulin, glucose, glucose infusion rate and counterregulatory
hormones during the clamps Mean plasma glucose levels
were 4.9±0.1 and 4.7±0.0 mmol/l during morning and
afternoon euglycaemia, respectively, vs 2.9±0.1 and 2.9±
0.1 mmol/l during corresponding morning and afternoon
hypoglycaemia (Fig. 1a). Insulin levels were similar during
morning and afternoon euglycaemic and hypoglycaemic
clamps (Table 1). Glucagon, adrenaline and cortisol
responses were all significantly increased during both
episodes of hypoglycaemia (Table 1). The glucagon
response to afternoon hypoglycaemia was significantly
attenuated compared with the response to morning hypo-
glycaemia. No significant differences in insulin levels,
glucose levels, glucose infusion rate and counterregulatory
hormone levels were observed between participants ArgArg
and GlyGly or between males and females.
Day 1 hypoglycaemic symptoms Total hypoglycaemic
symptom scores in the whole group were low during both
morning and afternoon euglycaemia, and did not differ
between ArgArg and GlyGly participants (Fig. 1b). During
hypoglycaemia, scores were approximately sixfold higher,
but did not differ between morning and afternoon hypo-
glycaemia, respectively, or between ArgArg and GlyGly
participants. When adrenergic symptoms were analysed
separately, there were no significant differences between
morning and afternoon hypoglycaemia, or between ArgArg
and GlyGly participants (data not shown).
Day 2 vasodilator response to salbutamol In response to
salbutamol, FBF significantly increased following both
euglycaemia (from 1.9±0.15 ml min
−1 [100 ml]
−1 to 11.9±
1.4 ml min
−1 [100 ml]
−1) and hypoglycaemia (from 2.2±
0.22 ml min
−1 [100 ml]
−1 to 16.2±1.5 ml min
−1 [100 ml]
−1)
with the increase tending to be greater following hypogly-
caemia (p=0.078, ANOVA, data not shown). This would be
consistent with increased β2-adrenergic receptor sensitivity
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β2-adrenergic receptor sensitivity was driven by a significant
increase in β2-adrenergic sensitivity after antecedent hypo-
glycaemia in ArgArg participants, with a maximal response
to salbutamol of 18.6±2.3 ml min
−1 [100 ml]
−1 following
hypoglycaemia and 12.2±2.0 ml min
−1 [100 ml]
−1 following
euglycaemia (p=0.019, ANOVA, Fig. 2a), whereas no such
effect was observed in GlyGly participants (Fig. 2b).
Heart rate and mean arterial pressure remained unchanged
until the final and highest dose of salbutamol was infused,
when both increased, suggestive of systemic effects (data
not shown).
Day 2 isoprenaline test Two ArgArg and two GlyGly
participants were excluded because of a technical error
with the isoprenaline test or because the required heart
rate response could not be reached or was already reached
with the lowest dose of isoprenaline. In the remainder (n=
12), the IC
25 measured after day 1 euglycaemia was higher
in ArgArg participants than in GlyGly participants (1.57±
0.25 vs 0.65±0.14 μg, p=0.008). In response to two bouts
of hypoglycaemia, the IC
25 tended to decrease in ArgArg
participants, suggestive of increased β-adrenergic sensitivity,
whereas the opposite was seen in GlyGly participants. This
diverging response to isoprenaline (the response following
euglycaemia minus hypoglycaemia for both genotypes)
following hypoglycaemia between the two subgroups was
statistically significant (p=0.047, Fig. 3).
Discussion
In the present study, two episodes of hypoglycaemia, a
stimulus sufficient to impair next day counterregulatory
Measurement Euglycaemia Hypoglycaemia
Morning Afternoon Morning Afternoon
Glucose (mmol/l) 4.9 (0.1) 4.7 (0.1) 2.9 (0.1)
a 2.9 (0.0)
a
GIR (μmol kg
-1 min
-1) 38.1 (1.1) 43.8 (1.2) 9.4 (1.7)
a 6.9 (1.6)
a
Insulin (pmol/l) 547 (28) 580 (47) 524 (40) 564 (60)
Glucagon (pmol/l) 22.4 (0.9) 20.1 (0.6) 47.4 (5.6)
a 32.8(3.5)
ab
Cortisol (μmol/l) 0.32 (0.03) 0.27 (0.04) 0.65 (0.04)
a 0.63 (0.05)
a
Adrenaline (nmol/l) 0.18 (0.02) 0.20 (0.04) 2.93 (0.40)
a 2.62 (0.27)
a
Noradrenaline (nmol/l) 1.37 (0.14) 1.32 (0.15) 1.64 (0.78) 1.78 (0.19)
Table 1 Plasma hormone and
glucose levels and glucose
infusion rate during morning
and afternoon glucose clamps
Values are means (SEM)
GIR, glucose infusion rate
ap<0.05 compared with euglycae-
mia;
bp<0.05 compared with
morning experiment
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pants [4, 5], did not decrease β2-adrenergic sensitivity in
either participant subgroup. In contrast, β2-adrenergic
sensitivity significantly increased following hypoglycae-
mia in participants who were homozygous ArgArg for the
β2-adrenergic receptor, but did not change in those who
were homozygous GlyGly. Analogously, hypoglycaemia
induced an increase in overall β-adrenergic sensitivity
measured with the isoprenaline test in ArgArg participants
relative to the GlyGly participants. These findings suggest
differences by genotype in the capacity to adapt to
repeated hypoglycaemia.
Our finding of increased rather than reduced β2-
adrenergic sensitivity after antecedent hypoglycaemia
argues against a direct role for reduced β2-adrenergic
sensitivity in the pathogenesis of hypoglycaemia unaware-
ness. This seems at odds with studies reporting reduced
overall β-adrenergic sensitivity in type 1 diabetic partic-
ipants with hypoglycaemia unawareness [14, 16–18, 32]o r
healthy participants following hypoglycaemia [15, 21].
However, in contrast to these studies, we used a well-
validated model for hypoglycaemia unawareness [5] and
studied healthy participants rather than type 1 diabetic
patients. In fact, the only other study that used a
comparable approach reported that a single nocturnal
hypoglycaemic episode increased next morning β-
adrenergic sensitivity in healthy participants, whereas it
decreased in patients with type 1 diabetes [15]. The authors
interpreted this increase in β-adrenergic sensitivity as a
compensatory response to prevent future hypoglycaemia,
an adaptive process that was apparently lost or exhausted in
patients with type 1 diabetes.
Our data raise the intriguing question as to whether the
disparate responses to antecedent hypoglycaemia in the
two genotype subgroups translate into a different suscep-
tibility to developing hypoglycaemia unawareness in
patients with type 1 diabetes. As mentioned above, one
previous study has reported increased overall β-adrenergic
sensitivity after hypoglycaemia in healthy non-diabetic
participants [15]. Our findings are in accordance with these
data insofar that the increase in β2-adrenergic sensitivity
was limited to the ArgArg participants. This increase in β2-
adrenergic sensitivity is potentially protective against future
hypoglycaemic events. Conversely, GlyGly participants,
who appear to lack this protective response, may be more
prone to hypoglycaemic events and the subsequent devel-
opment of hypoglycaemia unawareness. Although we
realise that findings in healthy participants cannot be
automatically translated to diabetic individuals, we specu-
late that this observation could potentially explain the
association between hypoglycaemia unawareness and the
GlyGly polymorphism for the β2-adrenergic receptor in
type 1 diabetic patients [10].
Overall β-adrenergic sensitivity, following antecedent
euglycaemia as reflected by the response to isoprenaline,
appeared lower in ArgArg participants than in GlyGly
participants, but tended to increase in ArgArg partic-
ipants and to decrease in GlyGly participants following
antecedent hypoglycaemia. However, although the effect
of antecedent hypoglycaemia on overall β-adrenergic
sensitivity in ArgArg participants was consistent with the
effect on β2-adrenergic sensitivity, these data should be
interpreted with caution. First, the time between the
second hypoglycaemic episode on day 1 and the isopren-
aline experiment on day 2 was at least 18 h, which is
longer than in other studies where β-adrenergic sensitivity
was measured either directly [21]o rw i t h i n~ 1 0ha f t e rt h e
hypoglycaemic event [15]. Second, the isoprenaline test
was performed shortly after β2-adrenergic sensitivity was
assessed with salbutamol. Systemic effects of the final
salbutamol dose could therefore have interfered with the
subsequent isoprenaline test. Since β2-adrenergic sensi-
tivity was the primary outcome, we deliberately chose to
perform the isoprenaline test afterwards, whereas repeat-
ing the entire clamp procedure for this purpose was
regarded as too great a burden for our participants. Third,
since we had to exclude four participants from the
analysis, we may have simply lacked the power to show
meaningful effects. Finally, our observation that the
differences in β-adrenergic sensitivity between the two
genotype subgroups only applied to the euglycaemic
experiments may indicate a baseline difference in adren-
ergic sensitivity or may reflect a general inaccuracy of the
test method without clinical relevance.
One other limitation that deserves comment is that we
did not formally test that hypoglycaemia unawareness was
induced on day 2. However, others have repeatedly shown
that two hypoglycaemic events are sufficient to impair
counterregulatory hormone responses to and symptomatic
awareness of next-day hypoglycaemia [4–6]. Furthermore,
there was a reduced glucagon response compared with the
preceding morning’s hypoglycaemia, indicating impending
counterregulatory impairment.
In conclusion, antecedent hypoglycaemia increased β2-
adrenergic sensitivity in young healthy participants ArgArg
for ADRB2 in contrast to GlyGly participants who did not
show increased β2-adrenergic sensitivity. We propose that
non-diabetic participants ArgArg for ADRB2 may to some
extent be protected against the development of some
aspects of hypoglycaemia unawareness, but that GlyGly
participants lack this protective mechanism. Further re-
search, especially in diabetic participants, is necessary to
explore this hypothesis. If this is confirmed in the type 1
diabetic population, it may help physicians to better
anticipate the risk of developing hypoglycaemia unaware-
ness when pursuing optimal glycaemic control.
Diabetologia (2011) 54:1212–1218 1217Acknowledgements We thank A. Rennings, F. Poelkens, A. Jansen
Van Rosendaal and J.-M. Kroese from the department of Internal
Medicine for their help with performing the experiments and M.
Coenen and B. Franke from the Department of Human Genetics for
their help with genotyping the participants, all from the Radboud
University Nijmegen Medical Centre. The results of this study were
presented at the Scientific Meeting of the American Diabetes
Association 2009 in New Orleans, LA, USA.
Duality of interest The authors declare that there is no duality of
interest associated with this manuscript.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Cryer PE (2008) The barrier of hypoglycemia in diabetes.
Diabetes 57:3169–3176
2. Dagogo-Jack SE, Craft S, Cryer PE (1993) Hypoglycemia-
associated autonomic failure in insulin-dependent diabetes melli-
tus. Recent antecedent hypoglycemia reduces autonomic
responses to, symptoms of, and defense against subsequent
hypoglycemia. J Clin Invest 91:819–828
3. Cryer PE (2002) Hypoglycaemia: the limiting factor in the
glycaemic management of type I and type II diabetes. Diabeto-
logia 45:937–948
4. Davis MR, Shamoon H (1991) Counterregulatory adaptation to
recurrent hypoglycemia in normal humans. J Clin Endocrinol
Metab 73:995–1001
5. Davis SN, Mann S, Galassetti P et al (2000) Effects of differing
durations of antecedent hypoglycemia on counterregulatory
responses to subsequent hypoglycemia in normal humans.
Diabetes 49:1897–1903
6. Heller SR, Cryer PE (1991) Reduced neuroendocrine and symp-
tomatic responses to subsequent hypoglycemia after 1 episode of
hypoglycemia in nondiabetic humans. Diabetes 40:223–226
7. Geddes J, Wright RJ, Zammitt NN, Deary IJ, Frier BM (2007) An
evaluation of methods of assessing impaired awareness of
hypoglycemia in type 1 diabetes. Diab Care 30:1868–1870
8. Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S,
Hougaard P, Thorsteinsson B (2001) Activity of angiotensin-
converting enzyme and risk of severe hypoglycaemia in type 1
diabetes mellitus. Lancet 357:1248–1253
9. Pedersen-Bjergaard U, Dhamrait SS, Sethi AA et al (2008) Genetic
variation and activity of the renin–angiotensin system and severe
hypoglycemia in type 1 diabetes. Am J Med 121:246–248
10. Schouwenberg BJ, Veldman BA, Spiering W et al (2008) The
Arg16Gly variant of the beta2-adrenergic receptor predisposes to
hypoglycemia unawareness in type 1 diabetes mellitus. Pharma-
cogenet Genomics 18:369–372
11. Leineweber K, Brodde OE (2004) Beta2-adrenoceptor polymor-
phisms: relation between in vitro and in vivo phenotypes. Life Sci
74:2803–2814
12. Green SA, Turki J, Innis M, Liggett SB (1994) Amino-terminal
polymorphisms of the human beta 2-adrenergic receptor impart
distinct agonist-promoted regulatory properties. Biochemistry
33:9414–9419
13. Liggett SB (2000) beta(2)-adrenergic receptor pharmacogenetics.
Am J Respir Crit Care Med 161:S197–S201
14. Korytkowski MT, Mokan M, Veneman TF, Mitrakou A, Cryer PE,
Gerich JE (1998) Reduced beta-adrenergic sensitivity in patients
with type 1 diabetes and hypoglycemia unawareness. Diab Care
21:1939–1943
15. Fritsche A, Stumvoll M, Grub M et al (1998) Effect of
hypoglycemia on beta-adrenergic sensitivity in normal and type
1 diabetic subjects. Diab Care 21:1505–1510
16. Berlin I, Grimaldi A, Payan C et al (1987) Hypoglycemic
symptoms and decreased beta-adrenergic sensitivity in insulin-
dependent diabetic patients. Diab Care 10:742–747
17. Berlin I, Grimaldi A, Bosquet F, Puech AJ (1986) Decreased beta-
adrenergic sensitivity in insulin-dependent diabetic subjects. J
Clin Endocrinol Metab 63:262–265
18. Trovik TS, Jaeger R, Jorde R, Sager G (1994) Reduced sensitivity
to beta-adrenoceptor stimulation and blockade in insulin depen-
dent diabetic patients with hypoglycaemia unawareness. Br J Clin
Pharmacol 38:427–432
19. Schwab KO, Menche U, Schmeisl G, Lohse MJ (2004)
Hypoglycemia-dependent beta2-adrenoceptor downregulation: a
contributing factor to hypoglycemia unawareness in patients with
type-1 diabetes? Horm Res 62:137–141
20. Trovik TS, Vaartun A, Jorde R, Sager G (1995) Dysfunction in the
beta 2-adrenergic signal pathway in patients with insulin depen-
dent diabetes mellitus (IDDM) and unawareness of hypoglycae-
mia. Eur J Clin Pharmacol 48:327–332
21. Trovik TS, Jaeger R, Jorde R, Sager G (1995) Reduced beta-
adrenergic sensitivity in healthy participants induced by hypogly-
cemia. Fundam Clin Pharmacol 9:181–186
22. Liu D, Moberg E, Kollind M, Lins PE, Adamson U, MacDonald
IA (1992) Arterial, arterialized venous, venous and capillary blood
glucose measurements in normal man during hyperinsulinaemic
euglycaemia and hypoglycaemia. Diabetologia 35:287–290
23. Deary IJ, Hepburn DA, MacLeod KM, Frier BM (1993)
Partitioning the symptoms of hypoglycaemia using multi-sample
confirmatory factor analysis. Diabetologia 36:771–777
24. de Galan BE, De Mol P, Wennekes L, Schouwenberg BJ, Smits P
(2006) Preserved sensitivity to beta2-adrenergic receptor agonists
in patients with type 1 diabetes mellitus and hypoglycemia
unawareness. J Clin Endocrinol Metab 91:2878–2881
25. Meijer P, Wouters CW, van den Broek PH et al (2008) Dipyridamole
enhances ischaemia-induced reactive hyperaemia by increased
adenosine receptor stimulation. Br J Pharmacol 153:1169–1176
26. Lenders J, Janssen GJ, Smits P, Thien T (1991) Role of the wrist
cuff in forearm plethysmography. Clin Sci (Lond) 80:413–417
27. Cleaveland CR, Rangno RE, Shand DG (1972) A standardized
isoproteranol sensitivity test. The effects of sinus arrhythmia,
atropine, and propranolol. Arch Intern Med 130:47–52
28. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out
procedure for extracting DNA from human nucleated cells.
Nucleic Acids Res 16:1215
29. Ronaghi M (2003) Pyrosequencing for SNP genotyping. Methods
Mol Biol 212:189–195
30. Willemsen JJ, Ross HA, Jacobs MC et al (1995) Highly sensitive
and specific HPLC with fluorometric detection for determination
of plasma epinephrine and norepinephrine applied to kinetic
studies in humans. Clin Chem 41:1455–1460
31. deGalanBE,TackCJ,LendersJWetal(2002)Theophyllineimproves
hypoglycemia unawareness in type 1 diabetes. Diabetes 51:790–796
32. Berlin I,Grimaldi A, Landault Cet al (1988) Lack of hypoglycemic
symptoms and decreased beta-adrenergic sensitivity in insulin-
dependent diabetic patients. J Clin Endocrinol Metab 66:273–278
1218 Diabetologia (2011) 54:1212–1218